PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Concizumab→

Concizumab PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1312299-39-0
Molecular formula
C6460H9964N1716O2014S44
Molecular weight
~145900 g/mol
Drug class
Tissue factor pathway inhibitor (TFPI) monoclonal antibodyprocoagulant biologic
Mechanism of action
Binds TFPI and inhibits its anticoagulant activity, increasing tissue factor-initiated thrombin generation and supporting haemostasis in haemophilia.
Indications / reported uses
  • Routine prophylaxis to prevent or reduce bleeding episodes in eligible adults and adolescents aged 12 years and older with haemophilia A or B with inhibitors under the US ALHEMO indication; not for treatment of acute bleeding episodes

Sources: US DailyMed — ALHEMO (concizumab-mtci) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Concizumab PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Concizumab Permitted Daily Exposure (PDE) report (the Concizumab PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Concizumab Occupational Exposure Limit (OEL) report (the Concizumab OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.